Canada - English - Health Canada

united therapeutics corporation - dinutuximab - solution - 3.5mg - dinutuximab 3.5mg - antineoplastic agents

Canada - English - Health Canada

amgen canada inc - rituximab - solution - 10mg - rituximab 10mg - antineoplastic agents

Canada - English - Health Canada

sandoz canada incorporated - rituximab - solution - 10mg - rituximab 10mg - antineoplastic agents

Canada - English - Health Canada

sanofi-aventis canada inc - isatuximab - solution - 100mg - isatuximab 100mg - antineoplastic agents

Canada - English - Health Canada

sanofi-aventis canada inc - isatuximab - solution - 500mg - isatuximab 500mg - antineoplastic agents

Israel - English - Ministry of Health

sanofi israel ltd - isatuximab - concentrate for solution for infusion - isatuximab 20 mg / 1 ml - isatuximab - sarclisa is indicated:- in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi).- in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Canada - English - Health Canada

pfizer canada ulc - rituximab - solution - 10mg - rituximab 10mg - antineoplastic agents

Canada - English - Health Canada

celltrion healthcare co ltd - rituximab - solution - 100mg - rituximab 100mg - antineoplastic agents

Canada - English - Health Canada

celltrion healthcare co ltd - rituximab - solution - 500mg - rituximab 500mg - antineoplastic agents

Canada - English - Health Canada

hoffmann-la roche limited - rituximab - solution - 10mg - rituximab 10mg - antineoplastic agents